Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Growth arrest-specific protein 2-like 3 (GAS2L3) is a cytoskeletal linker protein that binds both actin filaments and microtubules. It plays an essential role in coordinating cell division, particularly during late mitosis and cytokinesis, by localizing to the spindle midzone and midbody where it facilitates actin and microtubule organization. GAS2L3 is tightly regulated by cell cycle machinery (notably the APC/C Cdh1 complex) and is required for proper abscission, the final step of cell division. Deficiency in GAS2L3 impairs cytokinesis, leading to multinucleation and developmental defects including heart formation problems. Elevated expression of GAS2L3 correlates with poor prognosis in certain tumors such as glioma, indicating potential utility as a prognostic biomarker, but it is not established as a direct therapeutic target nor are there known drugs that act via this molecule[1][4][5][7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Growth arrest-specific protein 2-like 3 (GAS2L3).